Koichiro Yano
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Associate Professor |
|
Article types | Original article |
Language | English |
Peer review | Peer reviewed |
Title | Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. |
Journal | Formal name:Osteoporosis and sarcopenia Abbreviation:Osteoporos Sarcopenia ISSN code:24055263/24055255 |
Domestic / Foregin | Foregin |
Volume, Issue, Page | 7(3),pp.110-114 |
Author and coauthor | MOCHIZUKITakeshi, YANOKoichiro, IKARIKattunori, OKAZAKIKen |
Authorship | 2nd author |
Publication date | 2021/09 |
Summary | Objectives:To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.Methods:A total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated.Results:The percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point.Conclusions:The present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months. |
DOI | 10.1016/j.afos.2021.08.001 |
PMID | 34632114 |